Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo-controlled ...

2023 marks 25 years since the approval of the first biologic drug in rheumatology. In this Viewpoint, five rheumatology researchers discuss how biologic therapy has transformed clinical practice, ...

Antibiotic exposure in psoriasis patients is linked to increased biologic therapy discontinuation, with risk rising with multiple courses, suggesting gut microbiota alterations may play a role. The ...

Although 90% of patients with severe asthma choose to continue using a biologic, patients with worse disease control at baseline or with lower socioeconomic status (SES) may be more likely to cease ...

Please provide your email address to receive an email when new articles are posted on . Among patients with inflammatory bowel disease who received at least two biologic therapies, discontinuation of ...

Results from the NAVIGATOR study of tezepelumab showed that the new biologic therapy significantly reduced exacerbations requiring hospital stays and emergency department (ED) visits for adults and ...

There were 6137 AEs (84.9%) associated with biologic monotherapy and 1093 AEs (15.1%) associated with combined biologic therapy with MTX. The incidence rate for infections among patients treated with ...

Thousands of people around the world suffer from chronic bowel diseases. One such common disease is ulcerative colitis (UC), which causes inflammation and sores in the digestive tract of affected ...